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differed between conditioning intensities, we used 3 models
for prediction using the median ST2 concentrations for UM
FIC, UM RIC, and DFCI FIC as cutpoints.
In multivariate analysis including the age, disease status,
donor source, and HLA match, high ST2 predicted the
development of GVHD in UM FIC, and trended toward
signiﬁcance in the DFCI set (Table 1 Top). Patients with high
ST2 at D14 were at increased risk of D180 NRM for all
conditioning intensities, independent of the clinical charac-
teristics (Table 1 Bottom). High ST2 was not associated with
increased risk of relapse mortality 1 year after HSCT.
In conclusion, high ST2 early in HSCT identiﬁes patients at
high risk for acute GVHD and NRM following HSCT. This has
therapeutic consequences including increased monitoring
and potential preemptive interventions.
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Bronchiolitis obliterans syndrome (BOS) after allogeneic
HSCT is associated with high mortality and unknown path-
ogenesis. We present interim results from a prospective
phase II trial evaluating of montelukast for the treatment of
BOS after HSCT and studying BOS biology. Montelukast
interrupts cysteinyl leukotriene activity and may diminish
homing of activated cells to bronchioles and ﬁbrosis. Twenty-
three patients have enrolled with stable or decreasing
immunosuppression for 3 months prior and BOS diagnosed
by modiﬁed NIH criteria; 2 were withdrawn, and 19 have
completed primary endpoint. Participants ranged from 15-72
years, 13/23 female, most had moderate to severe disease
with baseline FEV1 of 46% predicted (24-73), and median
FEV1/VC 0.5 (0.29-0.78). Montelukast was well-tolerated and
no patient required escalation of BOS-directed therapy
during the evaluation period. All patients met criteria for
treatment success (<15% decline in 6 months), with FEV1
either increased 5-13% of predicted (n¼5), stable (n¼7), or
declined 5-13% (n¼6). FEV1 slope of decline was generated
using regression line of FEV1 value vs. days post-HSCT. At 6
months, slope was improved in 9 patients, stable in 9,
declined in 1. Other manifestations of cGVHD showed: 5/8 GI
GVHD improved and 3/8 stable; 5/10 liver cGVHD improved,4/10 stable, 1 worse, using NIH consensus staging. Survival of
the study cohort is 90% (19/21); 2 year survival is 84% (10/12),
twice published data (44%). Bronchoalveolar lavage (BAL)
from in non-infected patients at baseline revealed cysteinyl
leukotriene receptor expression on CD4 and CD8 T cells,
granulocytes, and eosinophils, thereby potentially impli-
cating these populations in BOS biology. While blood
leukotriene receptor expression on CD4 cells was similar to
normal donors, CD4 proportion was signiﬁcantly reduced in
BOS patients (P < 0.01). Other blood receptor levels of these
populations were similar between normal donors and
controls, although CD8 T cells trended toward decreased
receptor expression after treatment at 6 months and
decreased proportion of CD8 T cells at 2 years (p<0.04). B
cells were absent in BAL while present in blood. These data
suggest that: 1) montelukast is a safe and effective therapy
for BOS after allogeneic HSCT; 2) T cells, granulocytes, and
eosinophils (though not B cells) were associated with BOS in
BAL; and 3) cysteinyl leukotrienes may be a point of regu-
lation in the progression of BOS after HSCT.62
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Acute graft-versus-host disease (aGVHD) is primarily a T-
cell mediated process. Uric acid released from dying cells acts
as a danger signal that alerts the immune system to cell
death and promotes cytotoxic T cell responses. Elimination of
uric acid in mouse models reduces this immune response.
We hypothesized that lower serum uric acid levels at the
time of transplant may decrease the incidence of aGVHD.
Through record review, we recorded serum uric acid levels
from day -7 through day +6 from 43 historical control
patients who received myeloablative HCT (MRD, n¼32;
MUD, n¼11) at the Massachusetts General Hospital between
2007 and 2010, these patients received standard allopurinol.
We also obtained uric acid levels from 23 consecutive
patients (19-59 years) with hematologic malignancies in
complete remission (AML, n¼13; ALL, n¼8; MDS, n¼1; MPD,
n¼1) who were treated in a pilot trial using rasburicase as
part of a myeloablative conditioning regimen, followed by
GCSF-mobilized HLA-matched (MRD, n¼18; MUD, n¼5)
peripheral blood HCT. Urate oxidase (Rasburicase) was
administered beginning on the ﬁrst day of conditioning at
a dose of 0.20 mg/kg IV daily for 5 days starting from day -7.
GVHD prophylaxis for all patients consisted of cyclosporine
or tacrolimus/MTX for MRD transplants and tacrolimus/
MTX/ +/-ATG for MUD transplants. Out of the control group,
patients who developed aGVHD (grade 2+) had a similar
mean serum uric acid level over all days (2.82 mg/dl)
compared to patients who did not have aGVHD (2.86 mg/dl,
